Danaher Corporation

NYSE DHR

Data sourced from

and

Download Data

Danaher Corporation Book Value Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: 71.39

Danaher Corporation Book Value Per Share is 71.39 for the Trailing 12 Months (TTM) ending March 31, 2024, a 8.16% change year over year. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price.

Danaher Corporation Book Value Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 66.00, a 9.16% change year over year.
Danaher Corporation Book Value Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 60.47, a 13.67% change year over year.
Danaher Corporation Book Value Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was 53.19, a 22.04% change year over year.
Danaher Corporation Book Value Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was 43.59, a 8.37% change year over year.

NYSE: DHR

Danaher Corporation

CEO	Mr. Steven M. Rales
IPO Date	Jan. 5, 1979
Location	United States
Headquarters	2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
Employees	61,000
Sector	Healthcare
Industry	Diagnostics & research

Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Key trends